Occasional seizures, epilepsy, and inborn errors of metabolism

The Lancet Neurology

Volumn 13, Issue 7, 2014, Pages 727-739

  Dulac, Olivier ^a,b,c   Plecko, Barbara ^d   Gataullina, Svetlana ^b   Wolf, Nicole I ^b,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CEA Gif sur Yvette ^*  (Netherlands)

^c DIF   (France)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; FOLINIC ACID; GLUTAMATE TRANSPORTER; GLYCINE AMIDINOTRANSFERASE; GUANIDINOACETATE METHYLTRANSFERASE; GUANIDINOACETIC ACID; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; PYRROLINE 5 CARBOXYLATE DEHYDROGENASE; SULFITE OXIDASE; THIAMINE; TOLBUTAMIDE; VALPROIC ACID; VIGABATRIN;

ADOLESCENCE; AMINO ACID METABOLISM; BRAIN METABOLISM; CHILDHOOD DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EPILEPSY; FEBRILE CONVULSION; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INBORN ERROR OF METABOLISM; INFANT DISEASE; INFANTILE SPASM; KETOGENIC DIET; MUSCLE HYPOTONIA; MYOCLONUS EPILEPSY; NEWBORN PERIOD; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCASIONAL SEIZURE; PATIENT COUNSELING; PHENYLKETONURIA; PRIORITY JOURNAL; PROPIONIC ACIDEMIA; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SEIZURE;

ANIMALS; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS; METABOLISM, INBORN ERRORS; SEIZURES;

EID: 84902463335     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70110-3     Document Type: Review

References (124)

1. El Sabbagh S, Lebre A-S, Bahi-Buisson N, et al. Epileptic phenotypes in children with respiratory chain disorders. Epilepsia 2010, 51:1225-1235.
2. Wolf NI, Bast T, Surtees R Epilepsy in inborn errors of metabolism. Epileptic Disord 2005, 7:67-81.
3. Stanbury JBC, Wyngarrden JBR, Fredrickson DSY The metabolic bases of inherited diseases 1989, McGraw Hill, New York, NY.
4. Saudubray JM, van den Berghe C, Walter JJ Inborn metabolic diseases 2012, Springer Verlag, Heidelberg.
5. Rahman S, Footitt EJ, Varadkar S, Clayton PT Inborn errors of metabolism causing epilepsy. Dev Med Child Neurol 2013, 55:23-36.
6. Braissant O Current concepts in the pathogenesis of urea cycle disorders. Mol Genet Metab 2010, 100(suppl 1):S3-12.
7. Gataullina S, Dellatolas G, Perdry H, et al. Comorbidity and metabolic context are crucial factors determining neurological sequelae of hypoglycaemia. Dev Med Child Neurol 2012, 54:1012-1017.
8. Christiaens FJC, Mewasingh LD, Christophe C, Goldman S, Dan B Unilateral cortical necrosis following status epilepticus with hypoglycemia. Brain Dev 2003, 25:107-112.
9. Karimzadeh P, Tabarestani S, Ghofrani M Hypoglycemia-occipital syndrome: a specific neurologic syndrome following neonatal hypoglycemia?. J Child Neurol 2011, 26:152-159.
10. Barkovich AJ, Ali FA, Rowley HA, Bass N Imaging patterns of neonatal hypoglycemia. AJNR Am J Neuroradiol 1998, 19:523-528.
11. Farrant RD, Walker V, Mills GA, Mellor JM, Langley GJ Pyridoxal phosphate de-activation by pyrroline-5-carboxylic acid. Increased risk of vitamin B6 deficiency and seizures in hyperprolinemia type II. J Biol Chem 2001, 276:15107-15116.
12. Aicardi J Epileptic encephalopathies of early childhood. Curr Opin Neurol Neurosurg 1992, 5:344-348.
13. Dalla Bernardina B, Dulac O, Fejerman N, et al. Early myoclonic epileptic encephalopathy (E.M.E.E.). Eur J Pediatr 1983, 140:248-252.
14. Dalla Bernardina B, Aicardi J, Goutières F, Plouin P Glycine encephalopathy. Neuropadiatrie 1979, 10:209-225.
15. Nabbout R, Soufflet C, Plouin P, Dulac O Pyridoxine dependent epilepsy: a suggestive electroclinical pattern. Arch Dis Child Fetal Neonatal Ed 1999, 81:F125-F129.
16. Baxter P, Griffiths P, Kelly T, Gardner-Medwin D Pyridoxine-dependent seizures: demographic, clinical, MRI and psychometric features, and effect of dose on intelligence quotient. Dev Med Child Neurol 1996, 38:998-1006.
17. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006, 12:307-309.
18. Mills PB, Footitt EJ, Mills KA, et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 2010, 133:2148-2159.
19. Molinari F, Raas-Rothschild A, Rio M, et al. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet 2005, 76:334-339.
20. Johnson JW, Ascher P Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325:529-531.
21. Oztürk OH, Küçükatay V, Yönden Z, Aǧar A, Baǧci H, Delibaş N Expressions of N-methyl-D-aspartate receptors NR2A and NR2B subunit proteins in normal and sulfite-oxidase deficient rat's hippocampus: effect of exogenous sulfite ingestion. Arch Toxicol 2006, 80:671-679.
22. Demarque M, Villeneuve N, Manent J-B, et al. Glutamate transporters prevent the generation of seizures in the developing rat neocortex. J Neurosci 2004, 24:3289-3294.
23. Milh M, Becq H, Villeneuve N, Ben-Ari Y, Aniksztejn L Inhibition of glutamate transporters results in a "suppression-burst" pattern and partial seizures in the newborn rat. Epilepsia 2007, 48:169-174.
24. Plecko B, Paul K, Paschke E, et al. Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene. Hum Mutat 2007, 28:19-26.
25. Stockler S, Plecko B, Gospe SM, et al. Pyridoxine dependent epilepsy and antiquitin deficiency: clinical and molecular characteristics and recommendations for diagnosis, treatment and follow-up. Mol Genet Metab 2011, 104:48-60.
26. Dublin AB, Hald JK, Wootton-Gorges SL Isolated sulfite oxidase deficiency: MR imaging features. AJNR Am J Neuroradiol 2002, 23:484-485.
27. Struys EA, Nota B, Bakkali A, Al Shahwan S, Salomons GS, Tabarki B Pyridoxine-dependent epilepsy with elevated urinary α-amino adipic semialdehyde in molybdenum cofactor deficiency. Pediatrics 2012, 130:e1716-e1719.
28. Mouchegh K, Zikánová M, Hoffmann GF, et al. Lethal fetal and early neonatal presentation of adenylosuccinate lyase deficiency: observation of 6 patients in 4 families. J Pediatr 2007, 150:57-61.e2.
29. Mierzewska H, Schmidt-Sidor B, Jurkiewicz E, Bogdańska A, Kuśmierska K, Stepień T Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinate lyase deficiency-MRI, clinical, biochemical and neuropathological findings of Polish patients. Folia Neuropathol 2009, 47:314-320.
30. Banka S, Blom HJ, Walter J, et al. Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency. Am J Hum Genet 2011, 88:216-225.
31. Goutières F, Aicardi J Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neurol 1985, 17:117-120.
32. Leuzzi V, Mastrangelo M, Battini R, Cioni G Inborn errors of creatine metabolism and epilepsy. Epilepsia 2013, 54:217-227.
33. van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, et al. Phenotype and genotype in 101 males with X-linked creatine transporter deficiency. J Med Genet 2013, 50:463-472.
34. Bahi-Buisson N, Kaminska A, Nabbout R, et al. Epilepsy in Menkes disease: analysis of clinical stages. Epilepsia 2006, 47:380-386.
35. De Meirleir L, Lissens W, Denis R, et al. Pyruvate dehydrogenase deficiency: clinical and biochemical diagnosis. Pediatr Neurol 1993, 9:216-220.
36. Barnerias C, Boddaert N, Guiraud P, et al. Unusual magnetic resonance imaging features in Menkes disease. Brain Dev 2008, 30:489-492.
37. Sofou K, Steneryd K, Wiklund L-M, Tulinius M, Darin N MRI of the brain in childhood-onset mitochondrial disorders with central nervous system involvement. Mitochondrion 2013, 13:364-371.
38. DiMauro S, Hirano M, Kaufmann P, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv Neurol 2002, 89:217-229.
39. Katayama Y, Maeda K, Iizuka T, et al. Accumulation of oxidative stress around the stroke-like lesions of MELAS patients. Mitochondrion 2009, 9:306-313.
40. Bahi-Buisson N, Eisermann M, Nivot S, et al. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2. J Child Neurol 2007, 22:1147-1150.
41. Shimomura K, Hörster F, de Wet H, et al. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. Neurology 2007, 69:1342-1349.
42. Chugani HT, Shewmon DA, Sankar R, Chen BC, Phelps ME Infantile spasms: II. Lenticular nuclei and brain stem activation on positron emission tomography. Ann Neurol 1992, 31:212-219.
43. Mikaeloff Y, Plouin P, Dhondt JL, Ponsot G, Dulac O Clinical and EEG video-polygraphic features of epileptic spasms in a child with dihydropteridine reductase deficiency. Efficiency of hydrocortisone. Epileptic Disord 2000, 2:213-217.
44. Desguerre I, Pinton F, Nabbout R, et al. Infantile spasms with basal ganglia MRI hypersignal may reveal mitochondrial disorder due to T8993G MT DNA mutation. Neuropediatrics 2003, 34:265-269.
45. Lee YM, Kang HC, Lee JS, et al. Mitochondrial respiratory chain defects: underlying etiology in various epileptic conditions. Epilepsia 2008, 49:685-690.
46. Pineda M, Vilaseca MA, Artuch R, et al. 3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome. Dev Med Child Neurol 2000, 42:629-633.
47. Dalla Bernardina B, Fontana E, Darra F Myoclonic status in nonprogressive encephalopathies. Adv Neurol 2005, 95:59-70.
48. Salbert BA, Pellock JM, Wolf B Characterization of seizures associated with biotinidase deficiency. Neurology 1993, 43:1351-1355.
49. Colamaria V, Burlina AB, Gaburro D, et al. Biotin-responsive infantile encephalopathy: EEG-polygraphic study of a case. Epilepsia 1989, 30:573-578.
50. Seidner G, Alvarez MG, Yeh JI, et al. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998, 18:188-191.
51. Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain 2010, 133:655-670.
52. Leary LD, Wang D, Nordli DR, Engelstad K, De Vivo DC Seizure characterization and electroencephalographic features in Glut-1 deficiency syndrome. Epilepsia 2003, 44:701-707.
53. Leen WG, Wevers RA, Kamsteeg E-J, Scheffer H, Verbeek MM, Willemsen MA Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. JAMA Neurol 2013, 70:1440-1444.
54. Wibom R, Lasorsa FM, Töhönen V, et al. AGC1 deficiency associated with global cerebral hypomyelination. N Engl J Med 2009, 361:489-495.
55. Wolf NI, van der Knaap MS AGC1 deficiency and cerebral hypomyelination. N Engl J Med 2009, 361:1997-1998.
56. Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, et al. GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 2006, 67:480-484.
57. Gordon N Guanidinoacetate methyltransferase deficiency (GAMT). Brain Dev 2010, 32:79-81.
58. Bahi-Buisson N, El Sabbagh S, Soufflet C, et al. Myoclonic absence epilepsy with photosensitivity and a gain of function mutation in glutamate dehydrogenase. Seizure 2008, 17:658-664.
59. Barnerias C, Saudubray J-M, Touati G, et al. Pyruvate dehydrogenase complex deficiency: four neurological phenotypes with differing pathogenesis. Dev Med Child Neurol 2010, 52:e1-e9.
60. Klepper J, Fischbarg J, Vera JC, Wang D, De Vivo DC GLUT1-deficiency: barbiturates potentiate haploinsufficiency in vitro. Pediatr Res 1999, 46:677-683.
61. Striano P, Weber YG, Toliat MR, et al. GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. Neurology 2012, 78:557-562. the EPICURE Consortium.
62. Scheffer IE GLUT1 deficiency: a glut of epilepsy phenotypes. Neurology 2012, 78:524-525.
63. Pearl PL, Shukla L, Theodore WH, Jakobs C, Michael Gibson K Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain Dev 2011, 33:796-805.
64. Grapp M, Just IA, Linnankivi T, et al. Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency. Brain 2012, 135:2022-2031.
65. Kousi M, Lehesjoki A-E, Mole SE Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 2012, 33:42-63.
66. Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P Epilepsy syndromes in childhood and adolescence 2005, J Libbey, London. 4th edn.
67. Tassinari CA, Bureau-Paillas M, Dalla Bernardina B, et al. Lafora disease. Rev Electroencephalogr Neurophysiol Clin 1978, 8:107-122. (in French).
68. Tajima A, Ohashi T, Hamano S, Higurashi N, Ida H Gaucher disease patient with myoclonus epilepsy and a novel mutation. Pediatr Neurol 2010, 42:65-68.
69. Canafoglia L, Bugiani M, Uziel G, et al. Rhythmic cortical myoclonus in Niemann-Pick disease type C. Mov Disord 2006, 21:1453-1456.
70. Ganguly S, Gabani RU, Chakraborty S, Ganguly SB Sialidosis type I (cherry red spot-myoclonus syndrome). J Indian Med Assoc 2004, 102:174-175.
71. Zeng W-Q, Al-Yamani E, Acierno JS, et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet 2005, 77:16-26.
72. Gerards M, Kamps R, van Oevelen J, et al. Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome. Brain 2013, 136:882-890.
73. Kevelam SH, Bugiani M, Salomons GS, et al. Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy. Brain 2013, 136:1534-1543.
74. Debs R, Depienne C, Rastetter A, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol 2010, 67:126-130.
75. Serrano M, Rebollo M, Depienne C, et al. Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency. Mov Disord 2012, 27:1295-1298.
76. Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009, 50:1596-1607.
77. Visser NA, Braun KPJ, Leijten FSS, van Nieuwenhuizen O, Wokke JHJ, van den Bergh WM Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol 2011, 258:218-222.
78. Boyd SG, Harden A, Egger J, Pampiglione G Progressive neuronal degeneration of childhood with liver disease ("Alpers' disease"): characteristic neurophysiological features. Neuropediatrics 1986, 17:75-80.
79. Ferrari G, Lamantea E, Donati A, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA. Brain 2005, 128:723-731.
80. Nguyen KV, Østergaard E, Ravn SH, et al. POLG mutations in Alpers syndrome. Neurology 2005, 65:1493-1495.
81. Zschocke J, Ruiter JP, Brand J, et al. Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr Res 2000, 48:852-855.
82. Ofman R, Ruiter JPN, Feenstra M, et al. 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene. Am J Hum Genet 2003, 72:1300-1307.
83. Bindoff LA Mitochondrial function and pathology in status epilepticus. Epilepsia 2011, 52(suppl 8):6-7.
84. Iizuka T, Sakai F, Kan S, Suzuki N Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 2003, 61:1238-1244.
85. Surtees R, Wolf N Treatable neonatal epilepsy. Arch Dis Child 2007, 92:659-661.
86. Hartmann H, Fingerhut M, Jakobs C, Plecko B Status epilepticus in a neonate treated with pyridoxine because of a familial recurrence risk for antiquitin deficiency: pyridoxine toxicity?. Dev Med Child Neurol 2011, 53:1150-1153.
87. Belachew D, Kazmerski T, Libman I, et al. Infantile hypophosphatasia secondary to a novel compound heterozygous mutation presenting with pyridoxine-responsive seizures. JIMD Rep 2013, 11:17-24.
88. Krawitz PM, Murakami Y, Hecht J, et al. Mutations in PIGO, a member of the GPI-anchor-synthesis pathway, cause hyperphosphatasia with mental retardation. Am J Hum Genet 2012, 91:146-151.
89. Hoffmann GF, Schmitt B, Windfuhr M, et al. Pyridoxal 5'-phosphate may be curative in early-onset epileptic encephalopathy. J Inherit Metab Dis 2007, 30:96-99.
90. Plecko B, Paul K, Mills P, et al. Pyridoxine responsiveness in novel mutations of the PNPO gene. Neurology 2014, 82:1425-1433.
91. Mills PB, Camuzeaux SS, Footitt EJ, et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain 2014, 137:1350-1360.
92. Zempleni J, Hassan YI, Wijeratne SS Biotin and biotinidase deficiency. Expert Rev Endocrinol Metab 2008, 3:715-724.
93. Hyland K, Buist NR, Powell BR, et al. Folinic acid responsive seizures: a new syndrome?. J Inherit Metab Dis 1995, 18:177-181.
94. Gallagher RC, Van Hove JLK, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. Ann Neurol 2009, 65:550-556.
95. Steinfeld R, Grapp M, Kraetzner R, et al. Folate receptor α defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism. Am J Hum Genet 2009, 85:354-363.
96. Tabarki B, Al-Shafi S, Al-Shahwan S, et al. Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 2013, 80:261-267.
97. Narisawa K, Endo H, Miyabayashi S, Tada K Thiamine responsive pyruvate dehydrogenase deficiency. J Nutr Sci Vitaminol (Tokyo) 1992, Spec No:585-588.
98. Smithline HA, Donnino M, Greenblatt DJ Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. BMC Clin Pharmacol 2012, 12:4.
99. Sugden MC, Orfali KA, Holness MJ The pyruvate dehydrogenase complex: nutrient control and the pathogenesis of insulin resistance. J Nutr 1995, 125(suppl):1746S-1752S.
100. Steller J, Gargus JJ, Gibbs LH, Hasso AN, Kimonis VE Mild phenotype in a male with pyruvate dehydrogenase complex deficiency associated with novel hemizygous in-frame duplication of the E1α subunit gene (PDHA1). Neuropediatrics 2014, 45:56-60.
101. Kang H-C, Lee Y-M, Kim HD, Lee JS, Slama A Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007, 48:82-88.
102. Nabbout R, Mazzuca M, Hubert P, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010, 51:2033-2037.
103. El-Hattab AW, Hsu JW, Emrick LT, et al. Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation. Mol Genet Metab 2012, 105:607-614.
104. Schulze A, Bachert P, Schlemmer H, et al. Lack of creatine in muscle and brain in an adult with GAMT deficiency. Ann Neurol 2003, 53:248-251.
105. Mercimek-Mahmutoglu S, Connolly MB, Poskitt KJ, et al. Treatment of intractable epilepsy in a female with SLC6A8 deficiency. Mol Genet Metab 2010, 101:409-412.
106. de Koning TJ, Klomp LWJ Serine-deficiency syndromes. Curr Opin Neurol 2004, 17:197-204.
107. van der Crabben SN, Verhoeven-Duif NM, Brilstra EH, et al. An update on serine deficiency disorders. J Inherit Metab Dis 2013, 36:613-619.
108. Hitzert MM, Bos AF, Bergman KA, et al. Favorable outcome in a newborn with molybdenum cofactor type A deficiency treated with cPMP. Pediatrics 2012, 130:e1005-e1010.
109. Veldman A, Santamaria-Araujo JA, Sollazzo S, et al. Successful treatment of molybdenum cofactor deficiency type A with cPMP. Pediatrics 2010, 125:e1249-e1254.
110. Campeau PM, Valayannopoulos V, Touati G, et al. Management of West syndrome in a patient with methylmalonic aciduria. J Child Neurol 2010, 25:94-97.
111. Thakur V, Rupar CA, Ramsay DA, Singh R, Fraser DD Fatal cerebral edema from late-onset ornithine transcarbamylase deficiency in a juvenile male patient receiving valproic acid. Pediatr Crit Care Med 2006, 7:273-276.
112. Dealberto M-JCC Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007, 22:330-337.
113. Arya R, Glauser TA Pharmacotherapy of focal epilepsy in children: a systematic review of approved agents. CNS Drugs 2013, 27:273-286.
114. Dreifuss FE, Langer DH, Moline KA, Maxwell JE Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989, 39:201-207.
115. Arrigoni-Martelli E, Caso V Carnitine protects mitochondria and removes toxic acyls from xenobiotics. Drugs Exp Clin Res 2001, 27:27-49.
116. Kossak BD, Schmidt-Sommerfeld E, Schoeller DA, Rinaldo P, Penn D, Tonsgard JH Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine. Neurology 1993, 43:2362-2368.
117. Casarano M, Alessandrì MG, Salomons GS, et al. Efficacy of vigabatrin intervention in a mild phenotypic expression of succinic semialdehyde dehydrogenase deficiency. JIMD Rep 2012, 2:119-123.
118. Pearl PL, Gibson KM, Acosta MT, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology 2003, 60:1413-1417.
119. Anheim M, Maillart E, Vuillaumier-Barrot S, et al. Excellent response to acetazolamide in a case of paroxysmal dyskinesias due to GLUT1-deficiency. J Neurol 2011, 258:316-317.
120. Chen Y, Zhang Q, Shen T, et al. Comprehensive mutation analysis by whole-exome sequencing in 41 Chinese families with Leber congenital amaurosis. Invest Ophthalmol Vis Sci 2013, 54:4351-4357.
121. Schuster B, Knies K, Stoepker C, et al. Whole exome sequencing reveals uncommon mutations in the recently identified Fanconi anemia gene SLX4/FANCP. Hum Mutat 2013, 34:93-96.
122. Lamperti C, Fang M, Invernizzi F, et al. A novel homozygous mutation in SUCLA2 gene identified by exome sequencing. Mol Genet Metab 2012, 107:403-408.
123. Valayannopoulos V, Bajolle F, Arnoux J-B, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D,L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res 2011, 70:638-641.
124. Acker TM, Yuan H, Hansen KB, et al. Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol 2011, 80:782-795.